What is Valneva?
Founded in 2012 and headquartered in France, Valneva is a specialized biotechnology company dedicated to the creation of innovative vaccines for infectious diseases. Operating across Europe with facilities in France, Sweden, and the United Kingdom, Valneva combines rigorous scientific research with robust commercial vaccine production. The company's focus on preventative healthcare solutions positions it as a key player in the global pharmaceutical and chemical manufacturing sectors, addressing critical public health challenges through its advanced vaccine technologies.
How much funding has Valneva raised?
Valneva has raised a total of $749.8M across 5 funding rounds:
Debt
$27.6M
Debt
$100M
Grant
$27.2M
Corporate Investment
$95M
Debt
$500M
Debt (2016): $27.6M with participation from European Investment Bank
Debt (2020): $100M led by Orbimed and Deerfield
Grant (2022): $27.2M, investors not publicly disclosed
Corporate Investment (2022): $95M featuring Pfizer
Debt (2025): $500M, investors not publicly disclosed
Key Investors in Valneva
European Investment Bank
The European Investment Bank (EIB) is the lending arm of the European Union, providing financing for capital projects. Its involvement suggests a focus on large-scale, impactful ventures within the European economic landscape, particularly those aligned with EU policy objectives.
Pfizer
Pfizer is a global biopharmaceutical giant known for its extensive research, development, and manufacturing of medicines and vaccines. Its strategic investment in Valneva indicates a potential synergy in vaccine development or a validation of Valneva's technological capabilities.
Deerfield
Deerfield Management is a prominent investment firm specializing in the healthcare sector, known for its flexible funding models and focus on advancing healthcare innovation. Their participation highlights Valneva's appeal to sophisticated investors seeking to drive progress in medical solutions.
What's next for Valneva?
With substantial enterprise-level backing and a recent strategic investment, Valneva is poised for accelerated growth and innovation. The company's focus on developing and manufacturing vaccines for infectious diseases, coupled with its established European presence, provides a strong foundation for expanding its market reach and product portfolio. Future strategic initiatives are likely to center on advancing its pipeline of vaccine candidates, enhancing manufacturing capacities, and forging new partnerships to address emerging public health threats. The company's trajectory suggests a continued emphasis on scientific advancement and commercialization within the global vaccine market.
See full Valneva company page
